Anaesthesiology devices associated with adverse incidents. Anesthesiology devices associated with adverse incidents
Conditions
Interventions
Intervention 1: Intervention group: In addition to ipratropium bromide budesonide (0.25 mg), 2 nebulizers will be given every 12 hours from 1 hour before extubation until 48 hours after. Intervention
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients connected to a ventilator Requires intubation for more than 48 hours No treatment with corticosteroids or NSAIDs before enrollment No history of respiratory diseases including asthma, COPD Consent to participate in this study. History of allergy to the studied drugs Allergy to budesonide
Exclusion criteria
Exclusion criteria: Death within the first 24 hours. If extubation lasts more than a week. Withdrawal from continuing cooperation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: Before drug administration (at spontaneous) and 8 hours after spontaneous, immediately before extubation. Method of measurement: Monitoring device.;Heart rate. Timepoint: Before drug administration (at spontaneous) and 8 hours after spontaneous, immediately before extubation. Method of measurement: Monitoring device.;Oxygen saturation (SPO2). Timepoint: Before drug administration (at spontaneous) and 8 hours after spontaneous, immediately before extubation. Method of measurement: Monitoring device.;Respiratory rate. Timepoint: Before drug administration (at spontaneous) and 8 hours after spontaneous, immediately before extubation. Method of measurement: Monitoring device.;PCO2. Timepoint: Before drug administration (at spontaneous) and 8 hours after spontaneous, immediately before extubation. Method of measurement: Monitoring device.;HCO3. Timepoint: Before drug administration (at spontaneous) and 8 hours after spontaneous, immediately before extubation. Method of measurement: Monitoring device.;PH. Timepoint: Before drug administration (at spontaneous) and 8 hours after spontaneous, immediately before extubation. Method of measurement: Monitoring device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications (such as nausea, vomiting, loss of consciousness, decreased oxygen saturation, hypotension). Timepoint: Before drug administration (at spontaneous) and 8 hours after spontaneous, immediately before extubation. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Taghi Hashemi
Esfahan University of Medical Sciences
Outcome results
None listed